Comprehensive healthcare & pharmaceutical intelligence with 50,000 specialized agents
Project Name | Therapeutic Area | Discovery Phase | Success Probability | ASI Engine Recommendations | Status | Actions |
---|---|---|---|---|---|---|
NeuroCure-X | Neurology | Lead Optimization | 97.8% | Optimize binding affinity | On Track | |
CardioStat-7 | Cardiology | Preclinical | 98.5% | Enhance metabolic stability | On Track | |
ImmunoBoost-3 | Immunology | Target Validation | 96.2% | Expand target screening | Needs Attention | |
OncoCure-X9 | Oncology | Hit to Lead | 99.1% | Optimize selectivity profile | On Track |
Trial ID | Compound | Phase | Enrollment | Predicted Outcome | ASI Engine Recommendations | Status | Actions |
---|---|---|---|---|---|---|---|
CT-2025-089 | NeuroCure-X | Phase II | 87% | 98.2% Success | Optimize dosing protocol | On Track | |
CT-2025-102 | CardioStat-7 | Phase I | 95% | 99.1% Success | Continue as planned | On Track | |
CT-2025-078 | OncoCure-X8 | Phase III | 72% | 95.7% Success | Expand enrollment sites | Needs Attention | |
CT-2025-115 | MetaboSync-4 | Phase II | 91% | 97.5% Success | Refine biomarker analysis | On Track |
Facility | Efficiency | Quality Score | Capacity Utilization | ASI Engine Recommendations | Status | Actions |
---|---|---|---|---|---|---|
Boston Advanced | 99.2% | 99.7% | 92% | Optimize shift scheduling | Optimal | |
Singapore Precision | 98.7% | 99.5% | 95% | Enhance automation systems | Optimal | |
Zurich Innovation | 97.5% | 99.3% | 88% | Upgrade quality control systems | Upgrading | |
Tokyo Advanced | 98.9% | 99.6% | 91% | Implement predictive maintenance | Optimal |
Product | Therapeutic Area | Market Share | Growth | Patent Status | ASI Engine Recommendations | Actions |
---|---|---|---|---|---|---|
NeuroCure-X1 | Neurology | 32.5% | +8.2% | 12 years remaining | Expand to emerging markets | |
CardioStat-5 | Cardiology | 28.7% | +5.3% | 8 years remaining | Develop extended release formulation | |
ImmunoBoost-2 | Immunology | 18.5% | +12.7% | 15 years remaining | Expand indications | |
OncoCure-X7 | Oncology | 41.2% | +9.5% | 11 years remaining | Develop combination therapy |